AB Science OK’d to Start Masitinib Phase 3 Trial for Progressive MS

AB Science OK’d to Start Masitinib Phase 3 Trial for Progressive MS

315486

AB Science OK’d to Start Masitinib Phase 3 Trial for Progressive MS

The French Health Authority has approved AB Science’s request to launch a Phase 3 clinical trial to confirm the safety and effectiveness of its lead candidate masitinib in adults with primary progressive multiple sclerosis (PPMS) and nonactive secondary progressive MS (SPMS). “We are very excited to initiate this confirmatory phase III study with masitinib in progressive forms of multiple sclerosis,” Patrick Vermersch, MD, PhD, the trial’s principal investigator, said in a press release. He is…

You must be logged in to read/download the full post.